Audit: QRS - Phosphatidylserine for Health & Longevity

Audit conducted on 22/08/2026 02:17 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to the ER: protocol cells to ER lines 341/343/349/351/353/355, time cells to line 401, benefits to lines 146–199, risks to lines 224–270, gates to lines 290–319, markers and cadence to lines 429–441, qualitative items to lines 445–450.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“possible memory help”, “the second contested”, “Standing remains unresolved” and the marker targets “no established target” / “Track change from the individual’s own baseline” all mirror the ER hedging.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Pregnancy and lactation remain under Contraindications, not Key Interactions; speculative benefits and risks stay in the Speculative tier.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER “Populations who should avoid” list; Key Interactions only from the ER interaction bullets. No Benefit- or Risk-Modifying Factor is surfaced as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, NCT identifiers, author names, or brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Sober, sponsor-aware framing of the ER Conclusion is carried through, including “Almost every trial was funded by a seller”.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Doses, thresholds, and biomarker targets are given concretely, enabling action without overselling.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated descriptively (“Evening dosing reserved for a documented raised night-time cortisol”), not as an instruction to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives directed at a reader; the footer disclaimer is template text.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Protocol cells report the regimens used in the trials rather than prescribing them.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns appear anywhere in the populated spans.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms used (cortisol, thrombocytopenia, docosahexaenoic acid) are necessary and carried from the ER.
2.8	Information is presented in a concise and very compact manner	🟢	Benefits and Risks are reduced to bare tier headings; interaction items to label plus drug list; protocol subs to one or two clauses.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Split dosing, four-point salivary cortisol curves, and cortisol-to-DHEA-S ratios assume a proactive, self-quantifying reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Three-times-daily dosing with meals and a twice-run baseline cognitive battery are presented without hedging on inconvenience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Nine-marker monitoring panel and a defined 12-week decision point are beyond general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The At-A-Glance surfaces the sponsor-funding problem and the unresolved standing, which is the decision-relevant weighting for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal register throughout (“gastrointestinal upset”, “mood destabilisation”, “adrenal insufficiency”); the deliberately plain At-A-Glance wording is required by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed labels present verbatim at lines 446, 492, 537, 567, 583, 606, 634, 638–640, 789, and in the tier <strong> labels.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	67 data-qrs-var spans present and uniquely named, covering every variable referenced by the checklist with no gaps in the numbered sequences.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The non-variable template spans website="evidence_review", website="audit", and website="full_review" are untouched at lines 423, 426, 440.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped into the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard cognitive protocol”, “Stress and performance protocol”, “Best time of day” and all eleven interaction labels match the ER bold labels; the parenthetical gloss trimming permitted by 9.5 is the only deviation.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Marker names match the ER biomarker table verbatim; time-to-effect labels are drawn from the ER prose at line 401.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	The ER tier emojis and the “⚠️ Conflicted” markers are all stripped; tiers are conveyed by <strong> labels and CSS.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed against the ER: interaction bullets stripped of their mitigation clauses, benefits and risks reduced to bare headings, thirteen ER protocol bullets reduced to three cells.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> at line 1 and before the template comment at line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preamble text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header, footer, or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: phosphatidylserine_2026-0822-0002_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0822-0203.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual filename phosphatidylserine_2026-0822-0002_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Phosphatidylserine for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Phosphatidylserine for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/22/2026”, correctly derived from 2026-0822-0203.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header carries only the title and the template subline; the ER “Also known as” list is not reproduced.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the ER Conclusion (lines 470–474) to the two evidenced effects, their relative strength, the harm profile, the funding problem, and the verdict.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct Conclusion sentence at ER lines 470, 472, and 474.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “a fat”, “stress-hormone surge”, “memory help”, “digestive”; no acronyms and no clinical-register terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes, or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric results of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items come from “Populations who should avoid Phosphatidylserine” at ER lines 314–319.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER avoid-list entries are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six <li> elements at lines 570–578.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER trailing clauses “(too few clot-forming platelets)” and “where no safety data exist at any dose” are stripped; no dash-trailing content remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The 100 × 10⁹/L platelet threshold, the 14-day surgical window, the sunflower/third-party-testing exception, and the krill/fish scope are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	The ER uses no ranking notation in this list; the “<” style comparison is expressed in words as “below 100 × 10⁹/L”.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six such populations and the section is correctly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eleven items come from the ER interaction bullets at lines 290–310.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eleven ER interaction bullets are represented; none duplicates a Contraindication entry.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eleven <li> elements at lines 586–596.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER “Caution/Monitor”, rationale, and “Mitigation:” clause is stripped; the caffeine item drops the trial citation at ER line 310.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER example-drug list is retained; only the explanatory gloss “memory drugs that raise acetylcholine” is trimmed from the cholinesterase-inhibitor parenthesis, and the drug names survive.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	The ER parentheses hold plain comma-separated drug names with no ranking symbols; the QRS carries them through as such.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eleven interactions and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER “Therapeutic Protocol” bullets at lines 341, 343, 349, 351, 353, 355.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The two named regimens (cognitive, stress/performance) plus timing are the ER’s own lead bullets and the only ones carrying a dose or schedule decision.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Protocol section contains thirteen bullets, well above three.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine protocol spans carry substantive ER-derived content; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Chronic stress-axis onset, single-dose acute window, and cognitive onset are the only three timescales the ER gives (lines 349, 401).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	The two stress-axis cells, tied to the sole High-tier benefit, precede the cognitive cell, tied to a Medium-tier benefit.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time spans are populated; values “10 days – 3 weeks”, “90 minutes”, “6 weeks – 6 months” match ER line 401.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information at lines 349 and 401.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All nine benefit headings from ER lines 146–199 are carried across in their original tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 539, 542, 549, 555 with 1, 3, 3, and 2 items respectively, matching the ER tier counts.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER subheading; every Magnitude: paragraph, p-value, confidence interval, and sponsor note is dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers contain items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight risk headings from ER lines 224–270 are carried across in their original tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 608, 611, 617, 623 with 1, 2, 2, and 3 items respectively, matching the ER tier counts.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER subheading; the case report, dose thresholds, and Magnitude: paragraphs are all dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers contain items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Every row comes from the ER “Monitoring Protocol & Defining Success” biomarker table at lines 431–441.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER biomarkers are present in ER order, with targets and rationales matching lines 433–441.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 779 carries baseline, 4-week salivary curve, 12-week primary measure, and 6–12-month retesting, condensed from ER line 429.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items come from the ER qualitative marker list at lines 445–450.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers are present verbatim, none omitted or added.

Issues 22/08/2026 02:17

Pass rate 100.00%. No issues found.

Issues 22/08/2026 02:09

1. 2.4 / 2.5 / 2.6 / 2.9 — Imperative dosing instruction: [time_2_sub] (lines 515-518) reads “Dose 60–90 minutes before a stressor.”, an imperative that addresses the reader and delivers dosing advice; the ER (line 349) states only that “acute dosing 60–90 minutes before a stressor aligns exposure with need”.
2. 1.1 — Splitting claim conditioned on dose: [action_1_sub] (lines 456-459) states “Splitting reduces gastrointestinal upset above 200 mg”, whereas the ER (line 351) states “Splitting reduces gastrointestinal upset and is the sensible default above 200 mg” — the ER does not restrict the reduction to doses above 200 mg.

Fixes 22/08/2026 02:09

1. 2.4 / 2.5 / 2.6 / 2.9 — Imperative dosing instruction removed: [time_2_sub] changed from “Dose 60–90 minutes before a stressor.” to “Acute dosing 60–90 minutes before a stressor aligns exposure with need.”, matching the ER’s declarative phrasing and removing the direct address to the reader.
2. 1.1 — Splitting claim restored to ER wording: [action_1_sub] changed from “Splitting reduces gastrointestinal upset above 200 mg.” to “Splitting reduces gastrointestinal upset and is the sensible default above 200 mg.”, so the reduction is no longer conditioned on dose.